OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetings Remaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meetings with EU EMA and Australian TGA New York, New York--(Newsfile Corp. - April 27, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that it will be hosting a conference call on Thursday April 30, 2026 at 8:30am ET to review the data that supported the recent Patent Cooperation Treaty (PCT) international application for a OST-HER2 pharmacodynamic biomarker 1 (the "OST-HER2 Immune Signature") as a surrogate clinical efficacy endpoint. The OST-HER2 Immune Signature is expected to be used to support early market access in the second half of 2026 in the U.S via a Biologics License Application ("BLA") under the Accelerated Approval Program 2 (Accelerated Approval), in addition to Europe, the UK and Australia via Conditional Marketing Authorisations 3 (CMAs).